Erratum

Erratum Erratum (1446) Total Article Views Authors: Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M Published Date March 2012 Volume 2012:4 Pages 23 - 24 DOI: http://dx.doi.org/10.2147/CPAA.S31478 Received: 05 March 2012 Accepted: Published: 26 March 2012 Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications. 2010;2:225–236. On page 233, left-hand column, second paragraph, line 17 forward, it says: “The most common reasons for discontinuation were dizziness, confusion, somnolence, and asthenia, with the highest proportion of withdrawals in patients receiving retigabine 1200 mg/kg.72 In RESTORE 1, where retigabine was used at 1200 mg/kg, urinary or renal disorders were observed in 12% of patients.” In this passage, both instances of “retigabine 1200 mg/kg” should be “retigabine 1200 mg/day.” Read original article Post to: Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter Other articles by Professor Maurizio Taglialatela Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine Readers of this article also read: Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives Managing insulin resistance: role of liraglutide Mitochondrial therapy for Parkinson’s disease: Neuroprotective pharmaconutrition may be disease-modifying Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX mesalamine Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy Sedation in the intensive care setting